• Aptar announces that Nanopharm will provide development services for Aceso’s ACT-101 antisense oligonucleotide for CF

  Aptar Pharma has announced a deal with French biotech Aceso Therapeutics related to development of Aceso’s ACT-101 antisense oligonucleotide for the treatment of cystic fibrosis. According to Aptar, its subsidiary Nanopharm will provide development services… [Read more . . .]

• Copley Scientific launches Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX

  Inhaler testing specialist Copley Scientific has announced the launch of its new Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX. The company launched  Version 1 of Inhalytix+, a subscription-based cascade impactor software package, in August 2025. The TPK… [Read more . . .]

• Chinese NMPA approves Milestone and Everest’s Cardamyst etripamil nasal spray for the treatment of PSVT

  According to Milestone Pharmaceuticals and Everest Medicines, the Chinese National Medical Products Administration has approved Everest’s NDA for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia. Etripamil. Everest acquired development, manufacturing, and commercialization rights… [Read more . . .]

• Nemera launches DuoSpray bidose nasal delivery device for systemic drugs

  Drug delivery specialist Nemera has announced the launch of a new bidose nasal spray platform called DuoSpray that is intended for delivery of systemic drugs, including CNS therapies. The company says that the customizable intranasal… [Read more . . .]

• FDA accepts United Therapeutics’ sNDA to extend use of Tyvaso treprostinil inhalation solution for the treatment of IPF

  According to United Therapeutics, the FDA has accepted the company’s sNDA for Tyvaso treprostinil inhalation solution for the treatment of idiopathic pulmonary fibrosis. The FDA granted orphan drug designation to treprostinil for the treatment of… [Read more . . .]

• Lannett launches generic version of Advair Diskus in the US

• ENA Respiratory awarded almost AU$3 million funding to support Phase 1b trial of INNA-051 intranasal dry powder TLR2/6 agonist in patients with asthma

• Milestone Pharmaceuticals initiates Phase 3 ReVerA-301 trial of etripamil nasal spray (Cardamyst) for AFib-RVR

• Silo Pharma gets notice of allowance for Canadian patent covering SPC-15 intranasal therapy for PTSD

• Rein Therapeutic’s LTI-03 inhaled dry powder synthetic peptide gets Fast Track designation for the treatment of IPF

More news . . .